Group Antenatal Care and Delivery Project (GRAND)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04033003 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 25, 2019
Last Update Posted : January 6, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Antenatal care (ANC) has the potential to play a pivotal role in ensuring positive pregnancy outcomes for both mothers and their newborns. A critical component of all ANC is teaching women to recognize the major complications that account for the majority of preventable maternal and newborn deaths. Antenatal care provides an opportunity to promote a healthy lifestyle, to integrate positive health behaviors, and to develop a trusting relationship with a provider and the health system. While group ANC has been delivered and studied in high-resource settings for over a decade, it has only recently been introduced as an alternative to individual care in sub-Saharan Africa.
The goal of this research is to improve health literacy and reduce preventable maternal and newborn morbidities and mortality within highly vulnerable, low and non-literate populations that assume a disproportionate burden of poor pregnancy outcomes globally. This research examines a bold, new approach to ANC that takes provision of care out of clinic exam rooms into small groups of women grouped by gestational age in low resource settings with low and non-literate populations. Group ANC has the potential to shift the current clinical practice paradigm of antenatal care for highly vulnerable women to improve maternal and newborn outcomes both globally and domestically.
The investigators hypothesize that pregnant women randomized into group ANC will exhibit increased health literacy through: 1) increased birth preparedness and complication readiness (BPCR), including recognition of danger signs and knowledge of how to respond to such signs; 2) higher rates of care-seeking behaviors, including seeking care for problems identified during pregnancy, higher facility delivery rates, and increased attendance at postnatal and postpartum care; and 3) better clinical outcomes for themselves and their newborns than women who received the routine, individual ANC.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Antenatal Care | Behavioral: Group ANC | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1680 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Group Antenatal Care to Promote a Healthy Pregnancy and Optimize Maternal and Newborn Outcomes: A Cluster Randomized Controlled Trial |
| Actual Study Start Date : | July 29, 2019 |
| Estimated Primary Completion Date : | December 5, 2022 |
| Estimated Study Completion Date : | August 1, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group ANC
Intervention groups consist of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
|
Behavioral: Group ANC
Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman. |
|
No Intervention: Stand ANC
Individual standard antenatal care delivered at health facilities in Ghana
|
- Change in ability to identify danger signs in pregnancy [ Time Frame: Baseline and 3rd trimester ]Ability to identify danger signs in pregnancy will be measured utilizing a self-report, open ended, question that asks participants to identify warning signs that may occur during pregnancy (e.g. headache, vision changes, fever, vaginal bleeding, swollen face, etc.). Change will be measured by calculating the difference in the mean at baseline and 3rd trimester.
- Change in birth preparedness and complication readiness [ Time Frame: Baseline and 3rd trimester ]Change in the ability to identify a strategy for birth preparedness and complication readiness will be measured using a binary response (yes/no) to questions that ask participants if they have: (1) saved money, (2) identified birth facility for delivery, (3) identified emergency transportation to the facility, and (4) identified a blood donor. Modified from the Birth Preparedness and Complication Readiness Index
- Change in ability to identify newborn danger signs [ Time Frame: Baseline and 3rd trimester ]Ability to identify newborn danger signs will be measured utilizing a self-report, open ended, question that asks participants to identify newborn danger signs that may occur after delivery (e.g. poor suck, jaundice, difficulty/fast breathing, and convulsions). Change will be measured by calculating the difference in the mean at baseline and 3rd trimester.
- Attendance of ANC visits [ Time Frame: 6 weeks post-delivery ]Attendance of 4 or more ANC visits will be gleaned from data reported on the participant's ANC/health card.
- Place of delivery [ Time Frame: 6 weeks post-delivery ]Place of delivery will be measured using a self-report question (facility delivery, home delivery).
- Attendance at postnatal/postpartum check-ups for mother and newborn [ Time Frame: 6 weeks post-delivery ]Attendance of postnatal/postpartum check-ups will be gleaned from information on the participant's ANC/health card using a measure of 3 visits before 6 weeks for newborns and mothers.
- Birth outcome [ Time Frame: 6 week post-delivery ]Birth outcomes will be self-reported and measured as stillbirth, live birth, early neonatal mortality.
- Change in Health Literacy [ Time Frame: Baseline and 6 weeks post-delivery ]Change in Health Literacy will be measured using the Maternal Health Literacy Scale, a 12-item composite scale.The MaHeLi Scale is a validated measure that uses composite scores to measure health-seeking behaviors, competence and coping skills, and appraisal of health information. Change over time will be analyzed using between group analysis and calculating the difference in the mean from baseline to 6 weeks post-delivery.
- Change in ability to identify postpartum danger signs for mother [ Time Frame: Baseline and 3rd trimester ]Ability to identify danger signs after delivery will be measured utilizing a self-report, open ended, question that asks participants to identify warning signs that may occur after delivery (e.g. increased bleeding or large clots; weakness/fainting; fever; pain in abdominal or breast; painful urination, etc.). Change will be measured by calculating the difference in the mean at baseline and 3rd trimester.
- Change in ability to identify the recommended action steps when a problem is identified [ Time Frame: Baselin) and 3rd trimester ]Ability of mother to identify recommended action steps in response to danger signs will be measured by self-report using a question that asks participants to identify care-seeking behaviors to respond to danger signs that may occur before or after delivery (e.g. call for help, go to the hospital or health facility, identify someone to accompany you to the facility). Change will be measured by calculating the difference in the mean at baseline and 3rd trimester.
- Change in knowledge of family planning methods [ Time Frame: Baseline and 3rd trimester ]Knowledge of family planning methods will be measured by self-report using a question that asks participants to identify all the methods of family planning they know. Change will be measured by calculating the difference in the mean at baseline and 3rd trimester.
- Change in intent to use family planning [ Time Frame: Baseline and 3rd trimester ]Intent to use family planning methods will be measured by self-report using a binary (yes/no) question that asks participants their intent to use family planning after delivery. Change over time will be analyzed using between group analysis and calculating the difference in the mean from baseline to 3rd trimester
- Change in uptake of family planning [ Time Frame: 6 weeks post-delivery, 6 months post-delivery, and 1 year post-delivery ]Uptake of family planning will be measured by self-report using a questionnaire that asks participants if they are currently using family planning after delivery. Change over time will be analyzed using between group analysis and calculating the difference in the mean from baseline to 3rd trimester
- Change in interpersonal violence [ Time Frame: Baseline and 1 year post-delivery ]Interpersonal violence will be measured by self-report using a binary (yes/no) questionnaire that asks participants if they experienced violence in the past year, and if resources and support are available to them. Change over time will be analyzed using between group analysis and calculating the difference in the mean from baseline to 3rd trimester
- Experience of ANC care [ Time Frame: 6 weeks post-delivery ]Experience of ANC care will be measured by self-report using a binary (yes/no) questionnaire that asks participants about their experience regarding respectful care, satisfaction with care, and experience such as privacy and treatment with health system during their ANC visits.
- Completion of IPTp2 malaria prophylaxis during pregnancy [ Time Frame: 3rd Trimester ]Data gleaned from the participant's ANC/health record will be used to measure affirmative completion of IPTp2 malaria prophylaxis during pregnancy.
- Completion of least two tetanus toxoid vaccines during pregnancy [ Time Frame: 3rd trimester ]Data gleaned from the participant's ANC/health record will be used to measure if the participant received least two tetanus toxoid vaccines during pregnancy.
- Newborn weight in kg [ Time Frame: 6 weeks post-delivery ]Newborn weight in kg; these data will be retrieved from the participant's ANC/health card and measured as newborn weight in kg.
- Mother's hemoglobin at delivery in grams per deciliter (g/dl). [ Time Frame: 6 weeks post-delivery ]Mother's hemoglobin at delivery; these data will be retrieved from the participant's ANC/health card and measured as hemoglobin in grams per deciliter (g/dl).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Study for pregnant women |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- willingness to participate in the study
- less than 20 weeks' gestation 3) able to speak Dangme, Ga, Akan, Ewe, or English
- over the age of 15 years
Exclusion Criteria:
- No history of medical problems that would indicate the participant might be considered "high risk" (e.g., hypertension, insulin-dependent diabetes mellitus) and thus requiring a more individualized approach to care.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04033003
| Ghana | |
| Adawso Health Center | |
| Adawso, Ghana | |
| Adukrom Health Center | |
| Adukrom, Ghana | |
| Klo Agogo Polyclinic | |
| Agogo, Ghana | |
| Abiriw Clinic | |
| Akropong, Ghana | |
| St Martin's Hospital | |
| Akropong, Ghana | |
| Akuse Hospital | |
| Akuse, Ghana | |
| Nkurakan Health Center | |
| Koforidua, Ghana | |
| Tetteh Quarshie Hospital | |
| Mampong, Ghana | |
| Adoagyiri Health Center | |
| Nsawam, Ghana | |
| Djankrom Health Center | |
| Nsawam, Ghana | |
| Nsawam Health Center | |
| Nsawam, Ghana | |
| Nsawam Hospital | |
| Nsawam, Ghana | |
| Atua Hospital | |
| Somanya, Ghana | |
| Somanya Polyclinic | |
| Somanya, Ghana | |
| Study Director: | John EO Williams | Dodowa Health Research Centre | |
| Principal Investigator: | Jody R Lori, PhD | University of Michigan |
| Responsible Party: | Jody Rae Lori, Professor & Associate Dean for Global Affairs, University of Michigan |
| ClinicalTrials.gov Identifier: | NCT04033003 |
| Other Study ID Numbers: |
HUM00161464 R01HD096277 ( U.S. NIH Grant/Contract ) |
| First Posted: | July 25, 2019 Key Record Dates |
| Last Update Posted: | January 6, 2022 |
| Last Verified: | January 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Antenatal care Sub-Saharan Africa Ghana |

